The genomics and genetics of endometrial cancer

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
   Google Scholar
• Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16(1):14–22.
   PubMed Web of Science ®Google Scholar
• Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet. 2004;41(5):323–326.
   Google Scholar
• Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12(1):49–55.
   PubMed Web of Science ®Google Scholar
• Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S105–S143.
   Web of Science ®Google Scholar
• Ries LA, Young JL, Keel GE, Eisner MP Lin YD, Horner MJ. SEER Survival Monograph: Cancer Survival Among Adults: US. SEER Program, 1988–2001. Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub No 076215; 2007.
   Google Scholar
• Acharya S, Hensley ML, Montag AC, Fleming GF. Rare uterine cancers. Lancet Oncol. 2005;6(12):961–971.
   Web of Science ®Google Scholar
• Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8(5):261–271.
   PubMed Web of Science ®Google Scholar
• Mutter GL, Boynton KA, Faquin WC, Ruiz RE, Jovanovic AS. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res. 1996;56(19):4483–4486.
   Web of Science ®Google Scholar
• Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol. 2000;190(4):462–469.
   Web of Science ®Google Scholar
• Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56(2):403–412.
   Web of Science ®Google Scholar
• Mahboubi E, Eyler N, Wynder EL. Epidemiology of cancer of the endometrium. Clin Obstet Gynecol. 1982;25(1):5–17.
   PubMedGoogle Scholar
• Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–646.
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiang L, Fadare O, Kong B. A proposed model for endometrial serous carcinogenesis. Am JSurg Pathol. 2011;35(1):e1–e14.
   Web of Science ®Google Scholar
• Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995;26(11):1260–1267.
   Web of Science ®Google Scholar
• Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16(6):600–610.
   Web of Science ®Google Scholar
• Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol. 1995;19(4):417–432.
   Web of Science ®Google Scholar
• Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14(8):2263–2269.
   Web of Science ®Google Scholar
• Liang SX, Chambers SK, Cheng L, Zhang S, Zhou Y, Zheng W. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol. 2004;12(4):319–331.
   Web of Science ®Google Scholar
• Zheng W, Liang SX, Yi X, Ulukus EC, Davis JR, Chambers SK. Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol. 2007;26(1):38–52.
   Web of Science ®Google Scholar
• Zheng W, Liang SX, Yu H, Rutherford T, Chambers SK, Schwartz PE. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol. 2004;12(3):207–223.
   Web of Science ®Google Scholar
• Zhang X, Liang SX, Jia L, et al. Molecular identification of “latent precancers” for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol. 2009;174(6):2000–2006.
   Web of Science ®Google Scholar
• Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol. 2006;30(12):1519–1530.
   Web of Science ®Google Scholar
• Hamilton CA, Kapp DS, Chan JK. Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol. 2008;20(1):26–33.
   PubMed Web of Science ®Google Scholar
• Risinger JI, Maxwell GL, Chandramouli GV et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003;63(1):6–11.
   Web of Science ®Google Scholar
• Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst. 1994;86(16):1216–1221.
   Google Scholar
• Burks RT, Kessis TD, Cho KR, Hedrick L. Microsatellite instability in endometrial carcinoma. Oncogene. 1994;9(4):1163–1166.
   Web of Science ®Google Scholar
• Kobayashi K, Sagae S, Kudo R, Saito H, Koi S, Nakamura Y. Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type. Genes Chromosomes Cancer. 1995;14(2):128–132.
   Web of Science ®Google Scholar
• Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol. 1999;155(5):1767–1772.
   PubMed Web of Science ®Google Scholar
• Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A. 2003;100(10):5908–5913.
   Web of Science ®Google Scholar
• Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 1998;17(18):2413–2417.
   PubMed Web of Science ®Google Scholar
• Simpkins SB, Bocker T, Swisher EM, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet. 1999;8(4):661–666.
   PubMed Web of Science ®Google Scholar
• Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res. 1999;59(2):462–466.
   Web of Science ®Google Scholar
• Salvesen HB, MacDonald N, Ryan A, et al. Methylation of hMLHl in a population-based series of endometrial carcinomas. Clin Cancer Res. 2000;6(9):3607–3613.
   Web of Science ®Google Scholar
• Chiaravalli AM, Furlan D, Facco C, et al. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch. 2001;438(1):39–48.
   Web of Science ®Google Scholar
• Hardisson D, Moreno-Bueno G, Sanchez L, et al. Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability. Mod Pathol. 2003;16(11):1148–1158.
   Web of Science ®Google Scholar
• Swisher EM, Mutch DG, Herzog TJ, et al. Analysis of MSH3 in endometrial cancers with defective DNA mismatch repair. J Soc Gynecol Investig. 1998;5(4):210–216.
   Google Scholar
• Kawaguchi M, Yanokura M, Banno K, et al. Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. Int J Oncol. 2009;35(5):977–982.
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 1997;386(6627):761–763.
   PubMed Web of Science ®Google Scholar
• Fujii H, Jiang W, Matsumoto T, et al. Birt-Hogg-Dube gene mutations in human endometrial carcinomas with microsatellite instability. J Pathol. 2006;209(3):328–335.
   Web of Science ®Google Scholar
• Furlan D, Casati B, Cerutti R, et al. Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. J Pathol. 2002;197(5):603–609.
   Web of Science ®Google Scholar
• Vassileva V Millar A, Briollais L, Chapman W, Bapat B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res. 2002;62(14):4095–4099.
   PubMed Web of Science ®Google Scholar
• Catasus L, Matias-Guiu X, Machin P, Munoz J, Prat J. BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrial carcinomas with microsatellite instability. Lab Invest. 1998;78(11):1439–1444.
   Web of Science ®Google Scholar
• Sakaguchi J, Kyo S, Kanaya T, et al. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer. Gynecol Oncol. 2005;98(3):427–433.
   Web of Science ®Google Scholar
• Myeroff LL, Parsons R, Kim SJ, et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995;55(23):5545–5547.
   PubMed Web of Science ®Google Scholar
• Bilbao C, Ramirez R, Rodriguez G, et al. Double strand break repair components are frequent targets of microsatellite instability in endometrial cancer. Eur J Cancer. 2010;46(15):2821–2827.
   PubMed Web of Science ®Google Scholar
• Giannini G, Rinaldi C, Ristori E, et al. Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene. 2004;23(15):2640–2647.
   Web of Science ®Google Scholar
• Zighelboim I, Schmidt AP, Gao F, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol. 2009;27(19):3091–3096.
   Web of Science ®Google Scholar
• Lewis KA, Mullany S, Thomas B, et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res. 2005;65(16):7091–7095.
   Web of Science ®Google Scholar
• Risinger JI, Maxwell GL, Chandramouli GV et al. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. Cancer Res. 2005;65(12):5031–5037.
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–562.
   PubMed Web of Science ®Google Scholar
• Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1(2):170–185.
   PubMed Web of Science ®Google Scholar
• Shoji K, Oda K, Nakagawa S, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 2009;101(1):145–148.
   PubMed Web of Science ®Google Scholar
• Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65(23):10669–10673.
   PubMed Web of Science ®Google Scholar
• Risinger JI, Hayes AK, BerchuckA, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997;57(21):4736–4738.
   PubMed Web of Science ®Google Scholar
• Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57(18):3935–3940.
   Web of Science ®Google Scholar
• Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011;17(6):1331–1340.
   PubMed Web of Science ®Google Scholar
• Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW PIK3R1 (p85{alpha}) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011;71(12):4061–4067.
   PubMed Web of Science ®Google Scholar
• Salvesen HB, Stefansson I, Kalvenes MB, Das S, Akslen LA. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2002;94(8):2185–2191.
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R, Meyerson M. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer. 2009;101(7):1218–1219.
   Web of Science ®Google Scholar
• Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow PJ. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res. 1995;55(9):1922–1926.
   Web of Science ®Google Scholar
• Konopka B, Janiec-Jankowska A, Kwiatkowska E, et al. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. Hum Pathol. 2011;42(11):1710–1719.
   Web of Science ®Google Scholar
• Kang S, Seo SS, Chang HJ, Yoo CW, Park SY, Dong SM. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int J Gynecol Cancer. 2008;18(6):1339–1343.
   PubMed Web of Science ®Google Scholar
• Miyake T, Yoshino K, Enomoto T, et al. PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences. Cancer Lett. 2008;261(1):120–126.
   Web of Science ®Google Scholar
• Lu KH, Wu W, Dave B, et al. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res. 2008;14(9):2543–2550.
   Web of Science ®Google Scholar
• Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157–170.
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. 2010;2(53):53ra75.
   PubMed Web of Science ®Google Scholar
• Maxwell GL, Risinger JI, Gumbs C, et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 1998;58(12):2500–2503.
   PubMed Web of Science ®Google Scholar
• Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58(15):3254–3258.
   Web of Science ®Google Scholar
• Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92(11):924–930.
   PubMed Web of Science ®Google Scholar
• Zhou XP, Kuismanen S, Nystrom-Lahti M, Peltomaki P, Eng C. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet. 2002;11(4):445–450.
   Web of Science ®Google Scholar
• Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res. 2006;12(20 Pt 1):5932–5935.
   Web of Science ®Google Scholar
• Castellano E, Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer. 2011;2(3):261–274.
   PubMedGoogle Scholar
• Lester DR, Cauchi MN. Point mutations at codon 12 of C-K-ras in human endometrial carcinomas. Cancer Lett. 1990;51(1):7–10.
   Web of Science ®Google Scholar
• Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O, Rice JM. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res. 1990;50(19):6139–6145.
   Web of Science ®Google Scholar
• Boyd J, Risinger JI. Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. Mol Carcinog. 1991;4(3):189–195.
   Web of Science ®Google Scholar
• Sato S, Ito K, Ozawa N, Yajima A, Sasano H. Analysis of point mutations at codon 12 of K-ras in human endometrial carcinoma and cervical adenocarcinoma by dot blot hybridization and polymerase chain reaction. Tohoku JExp Med. 1991;165(2):131–136.
   Web of Science ®Google Scholar
• Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol. 1995;146(1):182–188.
   Web of Science ®Google Scholar
• Jones MW, Kounelis S, Hsu C, et al. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. Int J Gynecol Pathol. 1997;16(4):354–360.
   Web of Science ®Google Scholar
• Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88(4):814–824.
   Web of Science ®Google Scholar
• Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008;Chapter 10:Unit 10.11.
   Google Scholar
• Cohn DE, Mutch DG, Herzog TJ, et al. Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occur. Genes Chromosomes Cancer. 2001;32(4):295–301.
   Web of Science ®Google Scholar
• Mutter GL, Wada H, Faquin WC, Enomoto T. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. Mol Pathol. 1999;52(5):257–262.
   Google Scholar
• Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res. 1991;51(19):5308–5314.
   Web of Science ®Google Scholar
• Oda K, Okada J, Timmerman L, et al. PIK3CA cooperates with other phosphatidylinositol 3-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008;68(19):8127–8136.
   PubMed Web of Science ®Google Scholar
• Kim TH, Wang J, Lee KY, et al. The synergistic effect of conditional Pten loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action. J Oncol. 2010;2010:139087.
   Google Scholar
• Mutch DG, Powell MA, Mallon MA, Goodfellow PJ. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. Am J Obstet Gynecol. 2004;190(4):935–942.
   Web of Science ®Google Scholar
• Pappa KI, Choleza M, Markaki S, et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol. 2006;100(3):596–600.
   Web of Science ®Google Scholar
• Kang S, Lee JM, Jeon ES, et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer. 2006;119(6):1316–1321.
   PubMed Web of Science ®Google Scholar
• Mizumoto Y, Kyo S, Mori N, et al. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007;98(5):652–658.
   Web of Science ®Google Scholar
• Moreno-Bueno G, Sanchez-Estevez C, Palacios J, Hardisson D, Shiozawa T. Low frequency of BRAF mutations in endometrial and in cervical carcinomas. Clin Cancer Res. 2006;12(12):3865.
   Web of Science ®Google Scholar
• Feng YZ, Shiozawa T, Miyamoto T, et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res. 2005;11(17):6133–6138.
   PubMed Web of Science ®Google Scholar
• Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114–128.
   PubMed Web of Science ®Google Scholar
• Liao X, Siu MK, Chan KY, et al. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer. 2008;123(2):296–302.
   PubMed Web of Science ®Google Scholar
• Arafa M, Kridelka F, Mathias V et al. High frequency of RASSF 1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology. 2008;53(5):525–532.
   Web of Science ®Google Scholar
• Pallares J, Velasco A, Eritja N, et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol. 2008;21(6):691–699.
   PubMed Web of Science ®Google Scholar
• Nieminen TT, Gylling A, Abdel-Rahman WM, et al. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res. 2009;15(18):5772–5783.
   PubMed Web of Science ®Google Scholar
• Dewdney SB, Rimel BJ, Thaker PH, et al. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res. 2011;17(8):2120–2129.
   PubMed Web of Science ®Google Scholar
• Velasco A, Pallares J, Santacana M, et al. Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. Hum Pathol. 2011;42(2):185–193.
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105(25):8713–8717.
   PubMed Web of Science ®Google Scholar
• Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26(50):7158–7162.
   PubMed Web of Science ®Google Scholar
• Byron SA, Gartside MG, Wellens CL, et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 2008;68(17):6902–6907.
   PubMed Web of Science ®Google Scholar
• Machin P, Catasus L, Pons C, Munoz J, Matias-Guiu X, Prat J. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol. 2002;33(2):206–212.
   Web of Science ®Google Scholar
• Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol. 2002;15(10):1032–1037.
   Web of Science ®Google Scholar
• Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene. 2002;21(52):7981–7990.
   PubMed Web of Science ®Google Scholar
• Ashihara K, Saito T, Mizumoto H, Nishimura M, Tanaka R, Kudo R. Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia. Med Electron Microsc. 2002;35(1):9–15.
   Google Scholar
• Saegusa M, Hashimura M, Yoshida T, Okayasu I. beta-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer. 2001;84(2):209–217.
   Web of Science ®Google Scholar
• Brachtel EF, Sanchez-Estevez C, Moreno-Bueno G, Prat J, Palacios J, Oliva E. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Pathol. 2005;29(10):1322–1329.
   Web of Science ®Google Scholar
• Norimatsu Y, Moriya T, Kobayashi TK, et al. Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women. Ann Diagn Pathol. 2007;11(2):103–108.
   Web of Science ®Google Scholar
• Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 1999;59(14):3346–3351.
   PubMed Web of Science ®Google Scholar
• Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–6727.
   PubMed Web of Science ®Google Scholar
• Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 2011;224(3):328–333.
   PubMed Web of Science ®Google Scholar
• Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35(5):625–632.
   PubMed Web of Science ®Google Scholar
• Micci F, Teixeira MR, Haugom L, Kristensen G, Abeler VM, Heim S. Genomic aberrations in carcinomas of the uterine corpus. Genes Chromosomes Cancer. 2004;40(3):229–246.
   Web of Science ®Google Scholar
• Kato DT, Ferry JA, Goodman A, et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol. 1995;59(3):384–389.
   PubMed Web of Science ®Google Scholar
• Konski AA, Domenico D, Irving D, et al. Clinicopathologic correlation of DNA flow cytometric content analysis (DFCA), surgical staging, and estrogen/progesterone receptor status in endometrial adenocarcinoma. Am J Clin Oncol. 1996;19(2):164–168.
   Web of Science ®Google Scholar
• Newbury R, Schuerch C, Goodspeed N, Fanning J, Glidewell O, Evans M. DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol. 1990;76(2):251–257.
   Web of Science ®Google Scholar
• Pradhan M, Abeler VM, Danielsen HE, Trope CG, Risberg BA. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol. 2006;19(9):1227–1235.
   Web of Science ®Google Scholar
• Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer. 1994;74(6):1778–1783.
   Web of Science ®Google Scholar
• Rosenberg P, Wingren S, Simonsen E, Stal O, Risberg B, Nordenskjold B. Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator. Gynecol Oncol. 1989;35(1):50–54.
   PubMed Web of Science ®Google Scholar
• Moll UM, Chalas E, Auguste M, Meaney D, Chumas J. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol. 1996;27(12):1295–1300.
   Web of Science ®Google Scholar
• Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150(1):177–185.
   Web of Science ®Google Scholar
• Ambros RA, Sheehan CE, Kallakury BV et al. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol. 1996;9(12):1165–1169.
   Web of Science ®Google Scholar
• Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26(11):1268–1274.
   Web of Science ®Google Scholar
• Kovalev S, Marchenko ND, Gugliotta BG, Chalas E, Chumas J, Moll UM. Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol. 1998;29(6):613–619.
   Web of Science ®Google Scholar
• Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992;52(6):1622–1627.
   Web of Science ®Google Scholar
• Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol. 1999;74(3):468–471.
   Web of Science ®Google Scholar
• Sakuragi N, Watari H, Ebina Y, et al. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer. 2005;116(4):514–519.
   Web of Science ®Google Scholar
• Saffari B, Bernstein L, Hong DC, et al. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer. 2005;15(5):952–963.
   Web of Science ®Google Scholar
• Garg K, Leitao MM Jr, Wynveen CA, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol. 2010;23(1):80–92.
   Web of Science ®Google Scholar
• An HJ, Logani S, Isacson C, Ellenson LH. Molecular characterization of uterine clear cell carcinoma. Mod Pathol. 2004;17(5):530–537.
   Web of Science ®Google Scholar
• Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 2009;1795(1):1–15.
   Web of Science ®Google Scholar
• McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 2011;223(5):567–573.
   PubMed Web of Science ®Google Scholar
• Nagendra DC, Burke J 3rd, Maxwell GL, Risinger JI. PPP2R1A mutations are common in the serous type of endometrial cancer. Mol Carcinog. 2011. [Epub ahead of print.]
   Google Scholar
• Shih Ie M, Panuganti PK, Kuo KT, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol. 2011;178(4):1442–1447.
   Web of Science ®Google Scholar
• Morrison C, Zanagnolo V Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24(15):2376–2385.
   PubMed Web of Science ®Google Scholar
• Engelsen IB, Stefansson IM, Beroukhim R, et al. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol. 2008;32(2):307–316.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Santos L, Winterhoff B, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100(1):89–95.
   Web of Science ®Google Scholar
• Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8(5):1271–1279.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Siegel ER, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192(3):813–818.
   Web of Science ®Google Scholar
• Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22(15):3126–3132.
   PubMed Web of Science ®Google Scholar
• Diaz-Montes TP, Ji H, Smith Sehdev AE, et al. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol. 2006;100(1):139–144.
   Web of Science ®Google Scholar
• Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):3–9.
   Web of Science ®Google Scholar
• Odicino FE, Bignotti E, Rossi E, et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer. 2008;18(1):14–21.
   Web of Science ®Google Scholar
• Ren Y, Wang H, Zhou X, et al. Clinicopathological characteristics and her-2/neu status in chinese patients with uterine papillary serous carcinoma. ISRN Obstet Gynecol. 2011;2011:575327.
   Google Scholar
• Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol. 2001;22(2):122–126.
   Web of Science ®Google Scholar
• Singh P, Smith CL, Cheetham G, Dodd TJ, Davy ML. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. Int J Gynecol Cancer. 2008;18(6):1344–1351.
   Web of Science ®Google Scholar
• Santin AD, Bellone S, Van Stedum S, et al. Determination of HER2/ neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005;98(1):24–30.
   Web of Science ®Google Scholar
• Santin AD, Bellone S, Van Stedum S, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104(7):1391–1397.
   Web of Science ®Google Scholar
• Hayes MP, Douglas W, Ellenson LH. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol. 2009;113(3):370–373.
   PubMed Web of Science ®Google Scholar
• Catasus L, Gallardo A, Cuatrecasas M, Prat J. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol. 2009;22(4):522–529.
   PubMed Web of Science ®Google Scholar
• Milde-Langosch K, Bamberger AM, Goemann C, et al. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol. 2001;127(9):537–544.
   Web of Science ®Google Scholar
• Kato N, Watanabe J, Jobo T, et al. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol. 2003;129(4):222–226.
   Web of Science ®Google Scholar
• Cassia R, Moreno-Bueno G, Rodriguez-Perales S, Hardisson D, Cigudosa JC, Palacios J. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol. 2003;201(4):589–595.
   Web of Science ®Google Scholar
• Spruck CH, Strohmaier H, Sangfelt O, et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002;62(16):4535–4539.
   PubMed Web of Science ®Google Scholar
• Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 2001;413(6853):311–316.
   PubMed Web of Science ®Google Scholar
• Strohmaier H, Spruck CH, Kaiser P Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 2001;413(6853):316–322.
   PubMed Web of Science ®Google Scholar
• Suehiro Y, Okada T, Anno K, et al. Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clin Cancer Res. 2008;14(11):3354–3361.
   PubMed Web of Science ®Google Scholar
• Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol. 2006;19(8):1091–1100.
   Web of Science ®Google Scholar
• Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu LS, Ronnett BM. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33(10):1504–1514.
   PubMed Web of Science ®Google Scholar
• Alkushi A, Kobel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Cancer. 2010;29(4):343–350.
   Google Scholar
• Netzer IM, Kerner H, Litwin L, Lowenstein L, Amit A. Diagnostic implications of p16 expression in serous papillary endometrial cancer. Int J Gynecol Cancer. 2011;21(8):1441–1445.
   Web of Science ®Google Scholar
• Nakashima R, Fujita M, Enomoto T, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer. 1999;80(3–4):458–467.
   PubMed Web of Science ®Google Scholar
• Salvesen HB, Kumar R, Stefansson I, et al. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer. 2005;115(6):930–934.
   PubMed Web of Science ®Google Scholar
• Semczuk A, Boltze C, Marzec B, Szczygielska A, Roessner A, Schneider-Stock R. p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol. 2003;129(10):589–596.
   Web of Science ®Google Scholar
• Santin AD, Zhan F, Cane S, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer. 2005;92(8):1561–1573.
   Web of Science ®Google Scholar
• Konecny GE, Agarwal R, Keeney GA, et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol. 2008;109(2):263–269.
   PubMed Web of Science ®Google Scholar
• Sobel G, Nemeth J, Kiss A, et al. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol. 2006;103(2):591–598.
   Web of Science ®Google Scholar
• Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem. 1997;272(42):26652–26658.
   PubMed Web of Science ®Google Scholar
• Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003;362(9387):869–875.
   PubMed Web of Science ®Google Scholar
• El-Sahwi K, Bellone S, Cocco E, et al. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther. 2010;9(1):57–66.
   Web of Science ®Google Scholar
• Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277–279.
   PubMed Web of Science ®Google Scholar
• Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol. 2004;22(7):1242–1252.
   Web of Science ®Google Scholar
• Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol. 2002;100(6):1290–1295.
   Web of Science ®Google Scholar
• Scholten AN, Aliredjo R, Creutzberg CL, Smit VT. Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer. 2006;16(3):1379–1385.
   Web of Science ®Google Scholar
• Moreno-Bueno G, Hardisson D, Sarrio D, et al. Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 2003;199(4):471–478.
   PubMed Web of Science ®Google Scholar
• Mell LK, Meyer JJ, Tretiakova M, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004;10(16):5546–5553.
   Web of Science ®Google Scholar
• Singh M, Darcy KM, Brady WE, et al. Cadherins, catenins and cell cycle regulators: impact on survival in a gynecologic oncology group phase II endometrial cancer trial. Gynecol Oncol. 2011 ;123(2):320–328.
   Web of Science ®Google Scholar
• Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet. 1994;7(1):98–102.
   Web of Science ®Google Scholar
• Park JH, Lee BI, Song ES, Whang SO, Lee WY, Cho SJ. Hypermethylation of E-cadherin in endometrial carcinoma. J Gynecol Oncol. 2008;19(4):241–245.
   PubMedGoogle Scholar
• Yi TZ, Guo J, Zhou L, et al. Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma. Cancer Invest. 2011;29(1):86–92.
   PubMed Web of Science ®Google Scholar
• Montserrat N, Mozos A, Llobet D, et al. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum Pathol. 2011. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Blechschmidt K, Kremmer E, Hollweck R, et al. The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas. Diagn Mol Pathol. 2007;16(4):222–228.
   PubMedGoogle Scholar
• Singh M, Spoelstra NS, Jean A, et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008;21(7):912–923.
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278–3285.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415–5419.
   PubMed Web of Science ®Google Scholar
• Meyer LA, Slomovitz BM, Djordjevic B, et al. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer [abstract]. ASCO Meeting Abstracts. 2011:5016.
   Google Scholar
• Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer [abstract]. ASCO Meeting Abstracts. 2007:5516.
   Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065–3074.
   PubMed Web of Science ®Google Scholar
• Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol. 2011;8(5):302–306.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet. 2008;102(2):128–131.
   PubMed Web of Science ®Google Scholar
• Jewell E, Secord AA, Brotherton T, Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer. 2006;16(3):1370–1373.
   Web of Science ®Google Scholar
• Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(1):15–20.
   PubMed Web of Science ®Google Scholar
• Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: Challenges and opportunities. Cancer Biol Ther. 2012;13(1):1–13.
   PubMed Web of Science ®Google Scholar
• Bell DW. Our changing view of the genomic landscape of cancer. J Pathol. 2010;220(2):231–243.
   PubMed Web of Science ®Google Scholar
• Koul A, Willen R, Bendahl PO, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer. 2002;94(9):2369–2379.
   PubMed Web of Science ®Google Scholar
• Moreno-Bueno G, Femandez-Marcos PJ, Collado M, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res. 2007;67(5):1927–1934.
   PubMed Web of Science ®Google Scholar
• Sun H, Enomoto T, Fujita M, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol. 2001;115(1):32–38.
   Web of Science ®Google Scholar
• Cohen Y, Shalmon B, Korach J, Barshack I, Fridman E, Rechavi G. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol. 2010;116(1):88–91.
   Web of Science ®Google Scholar
• Manavi M, Bauer M, Baghestanian M, et al. Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium. Tumour Biol. 2001;22(5):299–309.
   Google Scholar